Declan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol, discusses the clinical significance of the phase 3 PROTEUS trial and addresses concerns about the study's use of ADT in the control arm.
Declan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol
Advertisement
Murphy is a consultant urologist, director of Genitourinary (GU) Oncology, and director of Robotic Surgery at the Peter MacCallum Cancer Centre and Professorial Fellow at the University of Melbourne.
Articles by Declan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol
The PRIMARY2 phase 3 trial found that PSMA PET-CT in men with normal or equivocal MRI results safely halved the number of prostate biopsies, maintained non-inferior detection of clinically significant cancer, and reduced insignificant cancer diagnosis by more than half.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
TULSA preserves penile length vs robotic prostatectomy in CAPTAIN trial
2
The UroOnc Minute: Optimizing Patient Follow-Up in Urologic Oncology, With Jason Hafron, MD
3
Can Aydogdu, MD on using ctDNA to predict nodal metastases at cystectomy
4
KEYNOTE-B15 data on enfortumab vedotin plus pembrolizumab in MIBC published in NEJM
5